ZUMA-23: A Global, Phase 3, Randomized Controlled Study of Axicabtagene Ciloleucel Versus Standard-of-Care as First-Line Therapy in Patients With High-Risk Large B-Cell Lymphoma

Jason R. Westin, MD, MS, FACP, reviews the background and study design of ZUMA-23, the first Phase III, randomized controlled study to evaluate CAR T-cell therapy as a first-line regimen in patients with high-risk LBCL.

Related Keywords

Jasonr Westin , ,Randomized Controlled Study ,Axicabtagene Ciloleucel Versus Standard Of Care ,First Line Therapy ,Patients With High Risk Largeb Cell ,Zuma 23 ,Zuma 23 Study ,Axicabtagene Ciloleucel ,Standard Of Care Largeb Cell Lymphoma ,Largeb Cell Lymphoma ,Lymphoma ,High Risk Largeb Cell Lymphoma ,First Line Treatments High Risk Largeb Cell Lymphoma ,Zuma 7 ,Zuma 1 ,Zuma 12 ,Axi Cel ,